Loading
Sanara MedTech Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by STUCKERT JAMES W, was filed 17 Oct 2019.
Sanara MedTech Inc.: what insiders have been doing
Sanara MedTech Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 15 filings came from 5 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 15 filings, this issuer sits below that mark. Since 2016, the database holds 9 purchases and 18 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 103.1 m USD and net income at -37.6 m USD.
There has been no open-market purchase by an insider of Sanara MedTech Inc. for at least a year. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
231
Thresholds
n/a
Buy Volume
€10M
9 ops. · all time
Sell Volume
€249,778
18 ops. · all time
Since the insiders bought
- +197.6%Entry US$10.50 · Close at T+365 US$31.25
- +197.6%Entry US$10.50 · Close at T+365 US$31.25
- +197.6%Entry US$10.50 · Close at T+365 US$31.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,367 of 26,246 companies
29.5
score / 100
Value22
Quality37
FCF yld0.7%
Earn yld-12%
EV/EBITDA34.2x
ROE-1.3%
Gross mgn93%
Net mgn-36%
Debt/EBITDA4.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$33.14
Analyst consensus
3 analysts3.00/5
US$35.00Target US$35.00(+6%)US$35.00
Income statement
RevenueUS$103.1M
Gross profitUS$95.6M93% margin
EBITDAUS$10.3M10% margin
Net income-US$37.6M-29.2% margin
Valuation
PER (trailing)58.2x
PER (forward)61.4x
P/Book38.4x
Beta1.19
Balance sheet & cash
Market capUS$304.5M
Total debtUS$48.2M
Free Cash FlowUS$2.1M
Debt / Equity612%
Profitability & ownership
ROE-1.3%
ROA7.6%
% insiders47.9%
% institutions18.5%
Last declaration on 16 September 2026
Declarations231 total
3,661 shares@ US$35.110.041% mcap38.7% of flowCommon StockSEC:0001493152-26-042898:0
5,539 shares0Common StockSEC:0001493152-26-027586:0
2,804 shares0Common StockSEC:0001493152-26-021296:0
378 shares@ US$20.010.0024% mcap22.6% of flowCommon StockSEC:0001493152-26-017079:0
2,804 shares0Common StockSEC:0001493152-26-012183:0
13,956 shares0Common StockSEC:0001493152-26-012181:0
12,687 shares0Common StockSEC:0001493152-26-012180:0
25,430 shares0Common StockSEC:0001493152-26-012179:0
596 shares@ US$18.873.4% of flowCommon StockSEC:0001493152-26-009530:0
414 shares@ US$20.442.5% of flowCommon StockSEC:0001493152-26-009406:0
491 shares@ US$20.443.0% of flowCommon StockSEC:0001493152-26-008596:0
714 shares@ US$19.9042.6% of flowCommon StockSEC:0001493152-26-008339:0
873 shares@ US$19.905.1% of flowCommon StockSEC:0001493152-26-008341:0
437 shares@ US$19.90100.0% of flowCommon StockSEC:0001493152-26-008337:0
149 shares@ US$19.90100.0% of flowCommon StockSEC:0001493152-26-008335:0
28,563 shares0Common StockSEC:0001493152-25-013702:0
2,324 shares@ US$30.8630.0% of flowCommon StockSEC:0001641172-25-024864:0
3,590 shares0Common StockSEC:0001641172-25-012722:0
3,277 shares0Common StockSEC:0001641172-25-012549:0
2,809 shares0Common StockSEC:0001641172-25-012551:0
3,746 shares0Common StockSEC:0001641172-25-012543:0
3,433 shares0Common StockSEC:0001641172-25-012542:0
3,277 shares0Common StockSEC:0001641172-25-012545:0
2,965 shares0Common StockSEC:0001641172-25-012547:0
4,929 shares@ US$30.8847.3% of flowCommon StockSEC:0001641172-25-011255:0
25 of 231 declarations
About Sanara MedTech Inc.
Sanara MedTech Inc. is a U.S.-based medical technology company listed on the Nasdaq market in the United States, focused on developing and commercializing products designed to improve clinical outcomes and reduce healthcare expenditures, with a core emphasis on the surgical market, chronic wounds, and skincare. From an equity research perspective, the stock is typically followed through earnings releases, product announcements, and SEC disclosures such as Form 4 insider transaction filings. The company’s headquarters are in Fort Worth, Texas, reinforcing its operational base in the U.S. healthcare ecosystem. ([ir.sanaramedtech.com](https://ir.sanaramedtech.com/?utm_source=openai))
Sanara MedTech traces its corporate roots to a Texas incorporation in 2001, and over time it has built a specialized portfolio around wound care and surgical recovery. Its strategy is not broad-based medtech scale, but rather focused niche execution: the company aims to pair clinical effectiveness with healthcare economics, targeting hospitals, surgeons, and medical distribution channels. Recent company communications reference products and initiatives including CellerateRX Surgical Powder, BIASURGE, and work related to OsStic, indicating an ongoing effort to expand the portfolio around surgical care and tissue repair. ([sec.gov](https://www.sec.gov/Archives/edgar/data/714256/000149315223013161/formars.pdf?utm_source=openai))
Read moreShow less
In competitive terms, Sanara operates in a specialized segment where differentiation depends on clinical evidence, reimbursement or purchasing access, and the ability to win adoption in hospital systems. A notable recent milestone was BIASURGE receiving an Innovative Technology contract from Vizient in January 2026. That matters because Vizient is a major U.S. group purchasing organization, so the contract can broaden access to BIASURGE across its healthcare customer network on contracted pricing and terms. The company also highlighted enhancements to its sales and distribution network, suggesting that commercial execution is becoming increasingly important alongside product development. ([ir.sanaramedtech.com](https://ir.sanaramedtech.com/news-releases/news-release-details/sanara-medtech-inc-reports-unaudited-preliminary-financial?utm_source=openai))
Recent highlights also include the publication of a peer-reviewed study assessing the economic and clinical value of CellerateRX in spine surgery wounds, preliminary full-year 2025 results, and 2026 guidance. For investors, Sanara MedTech should be viewed as a small-cap healthcare name with upside tied to product adoption, clinical validation, and successful commercialization in the U.S. market, but also with the usual execution risks associated with niche medtech commercialization. ([ir.sanaramedtech.com](https://ir.sanaramedtech.com/?utm_source=openai))
